Why Attend
Join us for the return of Phage Futures Europe, this November 2021 in Brussels, as we continue all-important discussions on translating new phage-based applications into clinical studies and beyond. Network and learn from multinational pharma, emerging biotechs, leading academics, investment representatives and regulatory bodies to discover how you can be at the forefront of the developing phage therapy market.
Introducing face-to-face interactions once again, Phage Futures Europe will help you maximise networking and commercial development with key industry players such as GSK, BiomX, Contrafect and more. This year, we discuss the viability of phage derived lysines in therapy, assess the therapeutic application of natural phages vs engineered phages and explore the clinical data surrounding the magisterial and compassionate use of phages in Europe.
Bacteriophages have seen continued investment and have adapted to global challenges, introducing commercial and marketable prospects for phage application. Phage Futures Europe explores the commercial applications of phages in poultry, aquaculture, biocontrol and skin microbiome, providing insights into the global design of phage products and acquiring pharmaceutical partnerships.
TALK TO OUR SPEAKERS ABOUT...
1. How to design a successful phage clinical trial
2. How to manipulate the microbiome with phage therapy to treat chronic diseases
3. The implications and safety requirements of administering phage therapy to patients
4. What indications are suitable for phage therapy within Europe?
5. How to obtain broad phage host range and maintain synergy within a fixed cocktail
6. Applications of phage related products as an alternative strategy to access the market
7. How magistral preparative supports the personalised medicine method
8. The route to appropriate clinical data: through innovative trial design
9. How to alleviate future multi-drug resistance through phage evolution research
10. What are the commercial pathways for phage therapies?
Advisory Board
Dr Gina Suh
Dr Todd Black
Jessica Sacher
Sandra Giannini
Ruby Lin
Who Will Be There
-
Kisaco Audience Breakdown ChartRegulatory / Government5%
-
Kisaco Audience Breakdown ChartService Providers5%
-
Kisaco Audience Breakdown ChartPhysicians / Clinicians15%
-
Kisaco Audience Breakdown ChartBiotechs20%
-
Kisaco Audience Breakdown ChartMultinationals25%
-
Kisaco Audience Breakdown ChartAcademics30%
-
Regulatory / Government5%
-
Service Providers5%
-
Physicians / Clinicians15%
-
Biotechs20%
-
Multinationals25%
-
Academics30%
TESTIMONIALS
SPEAKERS
Dr Peter Beyer
Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was instrumental in setting up the Global Antibiotic R&D Partnership (GARDP), a foundation that is developing new antibacterial treatments as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and WHO. Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. Prior to joining the Swiss civil service, Peter Beyer worked with the Ecologic Institute in Berlin on environmental law and policy.
Dr Todd Black
Frenk Smrekar
Dr Gina Suh
Sarah Dejebara
Dr. Jean-Paul Pirnay
Dr Shawna McCallin
Dr Steven Theriault
Dr. Steven Theriault is a passionate scientist with 20 years of research and entrepreneurial experience in generating biological solutions for biological problems. He founded Cytophage Technologies Inc., a company that uses natural, modified and synthetic bacteriophages to create a diversity of products that combat bacterial infections affecting human health, animal health and food security. Dr. Theriault’s goal is to enable bacteriophages to become mainstream for treating human and animal bacterial infections, thereby averting the WHO’s predicted AMR crisis and avoiding needless suffering.
Natalie Ma
Dr David Harper
My day job is as the CEO of Evolution Biotechnologies, moving environmentally friendly biological controls into the biomedical sector, based on the success of such agents in agriculture. This is based around low cost approaches minimising investor dilution while moving towards large potential markets.
Targets include the house dust mite, the main cause of asthma, where our novel approach underlies broad patent protection, and antibiotic resistant bacterial infections where individual veterinary treatments are already being undertaken. The company is building on its unique skillset in these key areas.
Dr. Cindy Fevre PhD
Dr. Lorenzo Corsini
Chandra Ghose
Tristan Ferry MD, PhD
Tobi Nagel
Dr Danish Malik
Dr. Bob Blasdel
I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.
I spend a lot of time thinking about what I'm going to eat next, why cows tend to orient themselves on a north/south axis, whether viruses are alive or non-living (or undead!), what it could have really been like to have lived under the laws of Solon, structure/function arguments in biology, and the value that I like to pretend the Oxford comma has for ameliorating run-on sentences.
Heather Fairhead
Matthew Tebeau
Dr Dave Ousterout
Dave Ousterout is a co-founder and Chief Scientific Officer for Locus Biosciences. Dave holds a PhD from Duke University where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His expertise is in protein engineering and early stage applications of new technologies to treat human diseases. At Locus, Dave is responsible for development of Locus’s crPhage platform and early stage product development. Prior to Locus, Dave was a consultant at McKinsey & Company.
Cara Casino
Dr Adam Ostrowski
Adam is a molecular microbiologist and an applications specialist at Cellexus International Ltd, where he helps customers find the optimal combination of bioreactor solutions offered by Cellexus and achieve the best possible results using our technology. Adam also helps develop new applications and technical solutions for our airlift-mixed single-use bioreactor range and delivers custom requests and improvements requested by our customers. Before joining Cellexus, Adam worked in bacteriophage treatment development for plant crop protection and during his academic career has studied Type VI Secretion system and functional proteins in bacterial communities.
Olivia McAuliffe
Dr. Edith Hessel
Dr Panos G. Kalatzis
Dr Cara Fiore
Viviana Clavijo
Sofia Corte-Real
Ruby Lin
AGENDA
Download your copy of the Phage Futures Europe 2021 agenda!
What you can expect from the Europe 2021 congress:
- 200+ participants from academic, industry, biotech and regulatory bodies onsite
- European and global phage thought leaders on the speaking agenda and ready to answer your big questions
- 2 days of furthering phage therapy
Key speakers include:
New content for 2021:
"First conference really focused on moving phage therapy and phage-related technologies forward. A great combination of regulatory, commercial, and scientific presentations." – Shawna McCallin, Phage Forward
Download 2021 Europe Agenda
Headline Partner
Cytophage Technologies
Website: https://cytophage.com/
Cytophage Technologies Inc. is a Canadian corporation that develops bacteriophage products to prevent and treat bacterial infections affecting human health, animal health and food security. Our technology allows us to generate bacteriophage products to address bacterial infections and overcome the inherent limitations of naturally occurring phages. With a number of bacteriophages in its animal health products pipeline, Cytophage is currently evaluating opportunities to enter the human health market including compassionate use and therapeutic applications related to COVID-19.
Our vision for Cytophage is that every hospital, every veterinarian and every agricultural facility will have a supply of Cytophage products to manage any incumbent or emergent bacterial infection or contamination.
Event Partner
Cellexus
Website: http://www.cellexus.com/
Cellexus was established in 2008, to develop a scalable single use bioreactor (SUB) for industrial and academic scientists to grow cell cultures in their laboratories, rapidly and in a controlled environment, for use in a wide range of applications including life sciences, brewing, biopharmaceutical and agricultural feed.
JAFRAL
Website: https://jafral.com/
JAFARAL is world’s leading CMO for production of bacteriophages, because it’s has more than 10 years’ experience in manufacturing of phages, other biologics production, large scale production and knowing GMP guidelines. Likewise, JAFRAL has all these years also been involved in plasmid DNA and recombinant proteins production at various levels. JAFRAL’s custom development and manufacturing services have helped developers across the globe to accelerate research and open up their laboratories for ground-breaking science and breakthrough discoveries.
Vesale Bioscience
Website: https://phage.health/
At Vésale Bioscience, we fight multi-antibiotics resistant infections (AMR) with our personalized phage therapy solutions:
-We have developed the fast diagnostic tool Inteliphage®, an automated Phagogram®, that will recommend the optimal phages association (2 or 3) to fight the patient’s bacteria.
-We GMP produce a library of phages as API for tailored magistral preparations.
This approach dramatically increases the success rate of AMR treatments and we expect to have our first sales in 2022.
Lead Media Partner
Phage Directory
Website: https://phage.directory/
Phage Directory promotes and accelerates the safe and effective use of phages in medicine, agriculture, and biotechnology around the world. We provide insight and support to communities and organizations interested in understanding and using phages.
Phage Directory can support you to:
- Stay up-to-date on new developments in phage research and phage therapy
- Understand the regulatory, scientific and tech landscape around phages and phage therapy
- Find and recruit individuals with phage expertise
- Develop phage-based technologies and products
- Organize phage and phage therapy-related conferences, seminars and workshops
Media Partners
Bacteriophage.news
Website: https://www.bacteriophage.news/
Please visit our website for more information.Beam Alliance
Website: https://beam-alliance.eu/
Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance is a strong Network of approx. 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.
BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
POSTER SESSION
Looking to showcase your recent work to the phage therapy community?
Our dedicated poster session is the perfect way to get your research noticed. Ideal for PhD students or Post-Doctoral researchers.
In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area.
Poster abstract submission deadline: 15th October 2021. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
For more information please contact [email protected]
APPLY HERE
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Returning Safely Measures
Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.
All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.
Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.
Venue
Pullman Brussels Centre Midi, Place Victor Horta 1, 1060 Bruxelles, Belgium
A stay at Pullman Brussels Centre Midi places you in the heart of Brussels, walking distance from Midi Market and Cantillon Brewery. This 4-star hotel is within close proximity of Law Courts of Brussels and Manneken Pis Statue.
Make yourself at home in one of the 237 air-conditioned rooms featuring refrigerators and MP3 docking stations. Wired and wireless Internet access is complimentary, and flat-screen televisions with digital programming provide entertainment. Private bathrooms have deep soaking bathtubs and complimentary toiletries. Conveniences include phones, as well as safes and desks.
Get 10% off your room rate, please note that in order to achieve the 10% discount you will need to become an Accor Member.
Click here to reserve your room.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.